Showing 3971-3980 of 5771 results for "".
- Tilak Healthcare Raises €7m to Deploy Its Remote Vision Monitoring Platformhttps://modernod.com/news/tilak-healthcare-raises-eur7m-to-deploy-its-remote-vision-monitoring-platform/2480381/Tilak Healthcare, a developer of mobile games with medical modules to monitor patients with chronic ophthalmological conditions, has announced a €7 million fundraising round managed by Elaia, with the participation of Swen Capital Partners, Matmut Innovation, and co-founder
- Collaboration Agreement Aims to Develop Orally Administered Treatment for Diabetic Macular Edema and Wet AMDhttps://modernod.com/news/collaboration-agreement-aims-to-develop-orally-administered-treatment-for-diabetic-macular-edema-and-wet-amd/2480380/Korea-based biopharmaceutical company Curacle announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation (TOI) for the development and commercialization of Curacle's CU06-RE, which is being examined as an orall
- iCare USA to Commercialize Oculo Software Solution Platform that Connects Doctors with Each Other and Their Patientshttps://modernod.com/news/icare-usa-to-commercialize-oculo-software-solution-platform-that-connects-doctors-with-each-other-and-their-patients/2480379/iCare USA’s parent company, Revenio, has announced its acquisition of Ocu
- Allergan to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopiahttps://modernod.com/news/allergan-to-present-new-data-on-investigational-agn-190584-for-the-treatment-of-presbyopia/2480377/Allergan announced that it will present new pooled analyses and post hoc results from the phase 3 trials of AGN-190584
- EyeGate Pharmaceuticals Closes Acquisition of Bayon Therapeuticshttps://modernod.com/news/eyegate-pharmaceuticals-closes-acquisition-of-bayon-therapeutics/2480376/EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’
- FDA Approves Genentech’s Port Delivery System, Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet AMDhttps://modernod.com/news/fda-approves-genentechs-port-delivery-system-susvimo-a-first-of-its-kind-therapeutic-approach-for-wet-amd/2480373/Genentech announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth fact
- Horizon Therapeutics: Newly Published Data Continue to Support Long-Term Efficacy of Tepezza for Thyroid Eye Disease (TED)https://modernod.com/news/horizon-therapeutics-newly-published-data-continue-to-support-long-term-efficacy-of-tepezza-for-thyroid-eye-disease-ted/2480371/Horizon Therapeutics announced additional data supporting the long-term efficacy of Tepezza for the treatment of TED. Data were published in
- New Essilor Vision Care Center Hosts First Virtual Global Varilux Summit Focused on Presbyopiahttps://modernod.com/news/new-essilor-vision-care-center-hosts-first-virtual-global-varilux-summit-focused-on-presbyopia/2480370/Essilor announced the creation of a digital event platform, the Essilor
- Retrotope Reports Positive Results from Studies of RT011 in Animal Models of Retinal Degenerationhttps://modernod.com/news/retrotope-reports-positive-results-from-studies-of-rt011-in-animal-models-of-retinal-degeneration/2480361/Retrotope announced that positive results from preclinical studies of RT011, the second compound to emerge from the company’s novel technology platform, are being reported
- Aurion Biotech Names Members of Medical Advisory Boardhttps://modernod.com/news/aurion-biotech-names-members-of-medical-advisory-board/2480358/Aurion Biotech announced the company’s medical advisory board, composed of the world’s most eminent ophthalmologists. The board will collaborate with the company’s executive team in clinical development, and is chaired by Edward Holland, MD, who was recently